Tag Archives: Immunomedics

ESMO: New Trodelvy breast, bladder cancer data show why Gilead’s going big for Immunomedics

Compared with the spate of multibillion-dollar buyouts last year, biopharma M&A has been relatively quiet in 2020—until last week, when Gilead Sciences surprised the market with its $ 21 billion purchase of Immunomedics. Now, two sets of new cancer data from Immunomedics’ first-in-class antibody-drug conjugate Trodelvy offer a glimpse into why Gilead paid such big money… Read More »